Strides Pharma Science Ltd

The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy. Two (out of the four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products. The cumulative market size for the acquired portfolio is around $57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $ 2.075 million (Rs 17.6 crore). Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products The company's consolidated net profit jumped 77.1% to Rs 87.95 crore on 14.7% increase in net sales to Rs 1153.67 crore in Q3 FY25 over Q3 FY24. The counter declined 1.61% to end at Rs 652.55 on Tuesday, 29 April 2025.Powered by Capital Market - Live

Arco Lab, a wholly owned subsidiary of Strides Pharma Science has incorporated a new wholly owned subsidiary viz., 'Pivot Path' on 10 April 2025. Powered by Capital Market - Live

Strides Pharma Global (SPG), a step-down wholly-owned subsidiary of Strides Pharma Science in Singapore, proposes to create a platform that shall foster introductions, collaborations, procurement and business engagement between pharmaceutical manufacturers and suppliers of India, China, and other Southeast-Asian countries. In this regard, it is proposed to acquire 100% stake in Amexel, Singapore, which will be utilized as the entity for the above business platform. SPG has entered into a Share Purchase Agreement to acquire 100% stake in Amexel for a nominal consideration of USD 10. Amexel, as WOS of SPG, shall focus on: 'h - in-licensing, technology transfers, and the procurement of technical and manufacturing expertise for the production of pharmaceutical products at Strides'' manufacturing facilities (or those of its affiliates) as well as other manufacturers in India. 'h - identifying qualified and approved suppliers, sourcing partners, and providers of APIs, Raw Materials and Packaging materials. 'h - building partnerships with distributors, commercial partners, and customers to support the supply, distribution, and commercialization of products across various territories. Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products. Powered by Capital Market - Live

Strides Pharma Science announced the change in designation of Arun Kumar (DIN: 00084845) from Executive Chairperson to Non-Executive Chairperson of the Company effective 05 April 2025. Arun Kumar, Founder and Executive Chairperson of the Company, has served in various positions on the Board of Strides since its inception. His current appointment as Executive Director is expiring on 06 April 2025. Upon successful transition of executive responsibilities to Badree Komandur (who was appointed as Managing Director and Group CEO effective 01 June 2024) and the Leadership team at Strides, Arun has opted to assume the role of Non-Executive Chairperson effective 05 April 2025.Powered by Capital Market - Live

Strides Pharma Science has appointed Mukta Arora (DIN: 07225715) as Independent Director of the Company effective 01 February 2025. Powered by Capital Market - Live

Net profit of Strides Pharma Science rose 77.07% to Rs 87.95 crore in the quarter ended December 2024 as against Rs 49.67 crore during the previous quarter ended December 2023. Sales rose 14.71% to Rs 1153.67 crore in the quarter ended December 2024 as against Rs 1005.77 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1153.671005.77 15 OPM %18.2312.87 - PBDT164.7068.49 140 PBT116.2819.04 511 NP87.9549.67 77 Powered by Capital Market - Live

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 30 January 2025.Powered by Capital Market - Live

OneSource Specialty Pharma (OneSource) is India's first specialty pharma Contract Development and Manufacturing Organization (CDMO). OneSource shall start trading on NSE and BSE from Friday, January 24, 2025 onwards, stated the company. Strides Pharma Science is engaged in developing and manufacturing a wide range of IP-led niche pharmaceutical products. It reported a consolidated net profit of Rs 93.23 crore in Q1 FY25 as against a net loss of Rs 131.34 crore posted in Q2 FY24. Revenue from operations grew 20.17% to Rs 1201.1 crore in the quarter ended September 2024. Powered by Capital Market - Live

Authum Investment & Infrastructure Ltd, Century Plyboards (India) Ltd, Tanla Platforms Ltd and Amber Enterprises India Ltd are among the other gainers in the BSE's 'A' group today, 01 January 2025.Strides Pharma Science Ltd surged 10.27% to Rs 727.55 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 1.32 lakh shares were traded on the counter so far as against the average daily volumes of 78858 shares in the past one month. Authum Investment & Infrastructure Ltd spiked 9.59% to Rs 1867.15. The stock was the second biggest gainer in 'A' group. On the BSE, 6551 shares were traded on the counter so far as against the average daily volumes of 8287 shares in the past one month. Century Plyboards (India) Ltd soared 9.46% to Rs 808. The stock was the third biggest gainer in 'A' group. On the BSE, 67435 shares were traded on the counter so far as against the average daily volumes of 8175 shares in the past one month. Tanla Platforms Ltd exploded 9.29% to Rs 734.45. The stock was the fourth biggest gainer in 'A' group. On the BSE, 68543 shares were traded on the counter so far as against the average daily volumes of 46356 shares in the past one month. Amber Enterprises India Ltd added 6.08% to Rs 7844. The stock was the fifth biggest gainer in 'A' group. On the BSE, 24875 shares were traded on the counter so far as against the average daily volumes of 40408 shares in the past one month. Powered by Capital Market - Live

CARE Ratings Ltd, Avalon Technologies Ltd, Adani Green Energy Ltd and Easy Trip Planners Ltd are among the other losers in the BSE's 'A' group today, 04 December 2024.Strides Pharma Science Ltd lost 5.11% to Rs 1513.1 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 34509 shares were traded on the counter so far as against the average daily volumes of 30958 shares in the past one month.CARE Ratings Ltd crashed 4.56% to Rs 1430. The stock was the second biggest loser in 'A' group.On the BSE, 4186 shares were traded on the counter so far as against the average daily volumes of 11904 shares in the past one month.Avalon Technologies Ltd tumbled 4.55% to Rs 875. The stock was the third biggest loser in 'A' group.On the BSE, 53104 shares were traded on the counter so far as against the average daily volumes of 1.01 lakh shares in the past one month.Adani Green Energy Ltd dropped 3.66% to Rs 1264.35. The stock was the fourth biggest loser in 'A' group.On the BSE, 2.38 lakh shares were traded on the counter so far as against the average daily volumes of 6.83 lakh shares in the past one month.Easy Trip Planners Ltd corrected 3.53% to Rs 16.38. The stock was the fifth biggest loser in 'A' group.On the BSE, 52.31 lakh shares were traded on the counter so far as against the average daily volumes of 23.43 lakh shares in the past one month.Powered by Capital Market - Live